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Our goal was to describe the presence of HIV drug resistance among HIV-1-infected, antiretroviral (ARV) na¨ ıve children and
adolescents in Latin America and to examine resistance in these children in relation to drug exposure in the mother. Genotyping
was performed on plasma samples obtained at baseline from HIV-1-infected participants in a prospective cohort study in Brazil,
Argentina, and Mexico (NISDI Pediatric Study). Of 713 HIV-infected children enrolled, 69 were ARV na¨ ıve and eligible for the
analysis. At enrollment, mean age was 7.3 years; 81.2% were infected with HIV perinatally. Drug resistance mutations (DRMs)
were detected in 6 (8.7%; 95% conﬁdence interval 3.1–18.2%) ARV-na¨ ıve subjects; none of the mothers of these 6 received ARVs
duringtheirpregnanciesandnoneofthechildrenreceivedARVprophylaxis.ReversetranscriptasemutationsK70RandK70Ewere
detected in 3 and 2 subjects, respectively; protease mutation I50V was detected in 1 subject. Three of the 6 children with DRMs
initiated ARV therapy during followup, with a good response in 2. The overall rate of primary drug resistance in this pediatric
HIV-infected population was low, and no subjects had more than 1 DRM. Mutations associated with resistance to nucleoside
reverse transcriptase inhibitors were the most prevalent.
1.Introduction
Primary HIV-1 drug resistance has been reported in up to
20% of HIV-infected adults in the United States and Europe
[1–3] and has led to recommendations that all treatment-
na¨ ıve adults undergo resistance testing when they enter care
[4]. Data on primary (or initial) resistance in HIV-infected
infants and children are more limited but have led to similar
recommendations [5]. Recent studies of infected infants in
the United States have demonstrated rates of primary resis-
tance to at least one antiretroviral (ARV) in the range of 19–
24%, with most being mutations associated with nonnucleo-
sidereversetranscriptaseinhibitor(NNRTI)resistance[6,7].
Rates reported from older children in the United Kingdom
are lower (3 of 44, 6.8%) [8]. In a study from Brazil, primary
resistance was seen in 7 of 26 (27%) perinatally infected
children [9], and a study from Argentina demonstrated
primaryresistancein5of22(23%)infectedinfantsbutmuch
lower rates (1 of 45, 2.2%) in infected children 1–14 years of
age [10]. When examined in some of these studies, maternal
ARV history did not generally provide a clear explanation for
the results seen in the infants and children.
The primary objectives of this analysis were to describe
the presence of HIV drug resistance mutations (DRMs) in
ARV treatment-na¨ ıve, HIV-1-infected children enrolled in
an observational study conducted in multiple sites in Latin
America and to examine subsequent treatment history and
response.
2.MaterialandMethods
In 2002, The Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD) began
enrollment to the NICHD International Site Development
Initiative (NISDI) pediatric protocol at 15 sites in Brazil,
Mexico, and Argentina [11]. The NICHD IRB, the data man-
agementandstatisticalcenterIRB,separatein-countryethics
committees, and national review boards (where required,2 Advances in Virology
i.e., Brazil) reviewed and approved the protocol. Informed
consent was obtained from either parents or guardians or
f r o ms u b j e c t sw h ow e r ea b l et op r o v i d ec o n s e n tb a s e du p o n
local laws. Assent was obtained from subjects >8y e a r so fa g e
when developmentally appropriate.
The following assessments were performed at 6-month
intervals as part of the NISDI pediatric protocol: medical
history, physical examination, hematology, ﬂow cytometry,
and HIV viral load testing. Blood samples were collected at
enrollment and yearly thereafter and sent to a central repos-
itory for storage. The study population for this investigation
was comprised of all ARV-na¨ ıve, HIV-1-infected children
who were enrolled in the NISDI Pediatric Protocol as of
February 1, 2005. Children born to mothers with known or
suspected HIV infection were considered to be perinatally
exposed. Children who had received ARVs during the ﬁrst 49
days of life for prophylaxis for mother-to-child transmission
(MTCT) of HIV were considered ARV na¨ ıve for purposes of
this investigation.
Plasma samples were assayed with the ViroSeq HIV-1
genotypingsystemv2.6,CeleraDiagnostics,attheMolecular
Virology Laboratory of the Instituto Nacional de Ciencias
M´ edicas y Nutricion Salvador Zubiran in Mexico City,
according to the manufacturer’s speciﬁcations. Reportable
DRMs were based on deﬁnitions of surveillance DRMs from
an international consensus document [12].
Characteristics of the study population are described
using simple descriptive statistics. The association of DRMs
with categorical characteristics was evaluated using the
Fisher’s exact test. For continuous scaled measures, the
Student’s t-test or Wilcoxon Rank Sums test (nonparametric
test) was used to assess diﬀerences between groups. Because
only a small number of DRMs was detected, no attempt
was made to model the risk of DRMs as a function of
subject characteristics. All analyses were performed using
SAS, Version 9.1.
3. Results
Of the 713 HIV-infected children and adolescents enrolled
in the NISDI Pediatric Protocol at clinical sites in Argentina,
Brazil, and Mexico as of February 1, 2005, a total of 85
subjects were ARV na¨ ıve and eligible for inclusion in this
study. Sixteen were excluded because they either did not
have a sample in the repository or viral DNA could not be
ampliﬁedfromtheirspecimen,leaving69subjectseligiblefor
the ﬁnal analysis.
Characteristics of the overall study population are shown
in Table 1. Most were perinatally HIV infected, and only
12.5% of the HIV-infected mothers of the perinatally
infected subjects had received ARVs during pregnancy or at
labor and delivery. DRMs were detected in samples from 6 of
the 69 eligible subjects (8.7%; 95% conﬁdence interval [CI]
3.1–18.2%).
Results from examining the association of DRMs with
characteristics of the study population (Table 1) indicate that
there were no diﬀerencesinthepresenceorabsenceofDRMs
accordingtosubject’scountryoforigin,age,gender,ormode
of HIV transmission (P ≥ .6). Among perinatally exposed
subjects, mother’s receipt of ARVs during pregnancy or at
labor and delivery was not associated with whether or not
DRMs were detected (P = .55). The presence or absence
of DRMs was not associated with CD4 percent, CD4 count,
CDC clinical classiﬁcation, or immunological category (P>
.09). The occurrence of DRMs was not associated with HIV-
1 RNA at or nearest the time when the resistance testing
specimen was collected; the geometric mean HIV-1 RNA
measure for those with and without DRMs detected was
24,592 and 46,806, respectively (P = .42). There was only
one death among study subjects; DRMs were not detected in
this subject’s specimen.
The subjects with DRMs identiﬁed ranged in age at time
of enrollment from 4 to 6 years of age and 50% were female.
All 6 subjects were perinatally HIV infected with subtype
B virus. None of the mothers of these 6 were known to
have received ARVs during pregnancy, and none of these
6 subjects received ARVs during the ﬁrst 49 days of life.
There were 3 diﬀerent mutations detected among the 6
subjects with DRMs: reverse transcriptase mutations K70R
(detected in 3 subjects), K70E (detected in 2 subjects), and
protease mutation I50V (detected in a single subject). None
of the subjects had more than one DRM detected in their
enrollment sample and none had DRMs associated with
resistance to nonnucleoside reverse transcriptase inhibitors
detected. Four of the six subjects (66.7%) were classiﬁed as
having no evidence of immune suppression.
Three of the 6 subjects with DRMs started ARV therapy
while being followed on the study. One subject started
zidovudine/lamivudine/efavirenz, and data at approximately
9 months after initiation of ARVs showed a higher viral load
and CD4 cell count continuing to decrease (data not shown).
Two other subjects started zidovudine/lamivudine/efavirenz
and zidovudine/lamivudine/nelﬁnavir respectively, and both
achieved virologic suppression.
4. Discussion
Among this population of HIV-1-infected children and
adolescents from Latin America who were ARV na¨ ıve at
time of enrollment with relatively low plasma viral loads
and relatively high CD4+ counts, DRMs were detected in
repository samples from 6 of 69 subjects (8.7%, 95% CI 3.1–
18.2%). The population we studied is likely representative
of the pediatric HIV population at these sites with expertise
in pediatric HIV and availability of ARVs, but we cannot
comment on how representative our population is of the
whole region. In comparison to other studies, this rate
of primary drug resistance is lower than that reported
in children in Northeast Brazil [9] and higher than the
0% rate reported in 24 children in Sao Paulo, Brazil [13]
(although reverse transcriptase mutation K219N was seen in
one subject in the latter study, which, by our deﬁnition [12],
yields a rate of 4.2%). Studies from the United States and
Argentina have shown higher rates in HIV-infected infants
[6, 7, 10]. However, all of these studies are quite small and
larger cohorts and datasets are necessary to document these
rates around the world and to examine changes in them as
access to ARVs expands. In addition, in several of these otherAdvances in Virology 3
Table 1: Characteristics of study population overall and according to whether or not DRMs were detected.
Characteristic Overall DRMs detected No DRMs detected P value∗
Number of subjects 69 6 (8.7%) 63
Country of origin:
Argentina 5 (7.2%) 0 (0.0%) 5
0.74 Brazil 55 (79.7%) 6 (10.9%) 49
Mexico 9 (13.0%) 0 (0.0%) 9
Age at enrollment (years):
Mean (SD) 7.3 (6.0) 5.2 (0.8) 7.5 (6.2) 0.64
Median 6.0 5.0 6.0
Gender:
Female 40 (58.0%) 3 (7.5%) 37 0.69
Male 29 (42.0%) 3 (10.3%) 26
Subject’s risk for HIV infection:
Blood product transfusion 1 (1.5%) 0 (0.0%) 1
1.00 Consensual sexual contact 8 (11.6%) 0 (0.0%) 8
Perinatal exposure 56 (81.2%) 6 (10.7%) 50
Unknown 4 (5.8%) 0 (0.0%) 4
Among perinatally infected, did mother take ARVs during pregnancy
or at labor and delivery?
Yes 7 (12.5%) 0 (0.0%) 7
0.55 No 44 (78.6%) 5 (11.4%) 39
Unknown 5 (8.9%) 1 (1.8%) 4
CD4 percent at or nearest to the time when the resistance testing
specimen was collected:
Mean (SD) 24.2 (10.9) 25.2 (8.6) 24.1 (11.2) 0.42
Median 24.0 28.0 23.0
<15% 11 (17.5%) 1 (9.1%) 10
0.64 15–24.9% 23 (36.5%) 1 (4.3%) 22
≥25% 29 (46.0%) 4 (13.8%) 25
Missing 60 6
CD4 absolute count (cells/mm3) at or nearest to the time when the
resistance testing specimen was collected:
Mean (SD) 779 (615) 769 (354) 780 (637) 0.65
Median 668 678 668
<200 cells/mm3 9 (13.2%) 0 (0.0%) 9
0.84 200–500 16 (23.5%) 1 (6.3%) 15
>500 43 (63.2%) 5 (11.6%) 38
Missing 10 1
CDC clinical classiﬁcation:
Category N 18 (26.5%) 4 (22.2%) 14
0.09
Category A 9 (13.2%) 1 (11.1%) 8
Category B 4 (5.9%) 0 (0.0%) 4
Category C 37 (54.4%) 1 (2.7%) 36
Missing 10 1
HIV-1 viral load (copies/mL) at or nearest to the time when the
resistance testing specimen was collected:
Mean 214,448 34,062 232,191
0.25 SD 522,665 31,248 544,831
Median 40,100 25,521 44,0004 Advances in Virology
Table 1: Continued.
Characteristic Overall DRMs detected No DRMs detected P value∗
Vital status of study subject:
Dead 1 (1.4%) 0 (0.0%) 1 1.00
Alive 68 (98.6%) 6 (8.8%) 62
∗The signiﬁcance of associations of categorical characteristics with DRMs was determined based on Fisher’s Exact test, while the association with continuous
scaled characteristics was based on the Student’s t-test (log10-transformed viral load) or nonparametric testing (Wilcoxon test).
studies and in ours, specimen collection was performed long
enough after infection that some DRMs may have become
undetectable,thusunderestimatingthetruerateofresistance
and also helping to explain the wide range of results seen.
T h eD R Mi d e n t i ﬁ e di n5o ft h e6s u b j e c t si no u r
study with primary resistance was associated with nucleoside
reverse transcriptase inhibitor resistance; the 6th subject had
a protease inhibitor-related DRM. None of the mothers of
these 6 children were known to have received ARVs during
pregnancy, and none of the 6 received ARV prophylaxis,
suggesting that the mothers were infected with the primary
resistant strain and transmitted this to their babies. A
limitation of our study is that we do not have samples from
the mothers to be able to assess this.
During the course of followup, 3 of the 6 subjects with
DRMs in our study began highly active ARV therapy, with
2 demonstrating a good response. While these numbers are
obviously too small to be able to draw any conclusions,
more such data on treatment outcomes in pediatric patients
with primary drug resistance are needed as ARV treatment
programs expand around the world.
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